EP3325444
Aðferðir til að framleiða N(4flúrbensýl)N(1metýlpíperídín4ýl) N'(4(2metýlprópýloxý) fenýlmetýl)karbamíð og tartratsalt og fjölbrigðaform C þess
- :EP einkaleyfi í gildi á Íslandi
- :19.7.2016
- :7.7.2021
- :16745321.6
- :30.8.2021
- :15.9.2021
- :18.7.2036
- :18.7.2026
- :31.7.2026
- :METHODS FOR PREPARING N-(4-FLUOROBENZYL)-N-(1-METHYLPIPERIDIN-4-YL)-N'-(4-(2-METHYLPROPYLOXY)PHENYLMETHYL)CARBAMIDE AND ITS TARTRATE SALT AND POLYMORPHIC FORM C
19.7.2016
7.7.2021
30.8.2021
15.9.2021
18.7.2026
- :Acadia Pharmaceuticals Inc.
- :12830 El Camino Real, Suite 400, San Diego, CA 92130, US
- :CARLOS, Marlon
- :Chula Vista, CA 91913, US
- :TANDEL, Sagun
- :San Diego, CA 92122, US
- :OLSSON, Roger
- :SE-21838 Bunkeflostrand, SE
- :HILLGREN, Mikael
- :75435 Uppsala, SE
- :FLEMING, Matthew, J.
- :CH-4800 Zofingen, CH
- :BOUDIER, Andreas, Philipp
- :CH-8003 Zurich, CH
- :WEBER, Beat, T.
- :CH-4800 Zofingen, CH
- :201562194725 P
- :20.7.2015
- :US
- :US2016042933
- :19.7.2016
- :C07D 211/58
: 6
: 10.8.2021
: 18.7.2022
: Sigurjónsson & Thor ehf.
: 7
: 1.7.2022
: 18.7.2023
: Patice ehf.
: 8
: 11.7.2023
: 18.7.2024
: Árnason Faktor ehf.
: 9
: 3.7.2024
: 18.7.2025
: Árnason Faktor ehf.
: 10
: 9.7.2025
: 18.7.2026
: Árnason Faktor ehf.